Dave Amarasena
Family · Staten Island, NYNPI 1831713163
Payments from drug & device makers
Across 112 payments — averaging $109.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$1K
- Boehringer Ingelheim$925
- Otsuka America Pharmaceutical, Inc.$897
- Regeneron Healthcare Solutions, Inc.$854
- Teva Pharmaceuticals USA, Inc.$848
- Sanofi$760
- plus $7K from 27 others
What the payments were for
- Travel & lodging$7166%
- Food & beverage$11,50694%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 15 | $1,323 |
| Boehringer Ingelheim | 8 | $925 |
| Otsuka America Pharmaceutical, Inc. | 7 | $897 |
| Regeneron Healthcare Solutions, Inc. | 7 | $854 |
| Teva Pharmaceuticals USA, Inc. | 7 | $848 |
| Sanofi | 7 | $760 |
| AstraZeneca(2 entities) | 8 | $759 |
| AbbVie | 4 | $493 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $449 |
| Genentech USA, Inc. | 3 | $437 |
| Calliditas Therapeutics US Inc. | 3 | $375 |
| Vanda Pharmaceuticals Inc. | 3 | $358 |
| Gilead | 3 | $348 |
| Sage Therapeutics, LLC | 3 | $296 |
| Optinose US, Inc. | 6 | $296 |
| Phathom Pharmaceuticals, Inc. | 2 | $255 |
| Viiv Healthcare Company | 2 | $243 |
| Axsome Therapeutics, Inc. | 2 | $241 |
| Novo Nordisk | 3 | $238 |
| GSK | 2 | $218 |
| Sumitomo Pharma America, Inc. | 1 | $150 |
| Cochlear Americas | 1 | $144 |
| Madrigal Pharmaceuticals | 1 | $135 |
| CSL Behring | 1 | $135 |
| Medtronic | 1 | $128 |
| Ultragenyx Pharmaceutical Inc. | 1 | $125 |
| Impel Pharmaceuticals Inc. | 1 | $125 |
| Idorsia Pharmaceuticals US Inc | 1 | $124 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $124 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $117 |
| Mylan Specialty L.p. | 1 | $109 |
| Coloplast | 1 | $102 |
| Advanced Oxygen Therapy Inc. | 1 | $87 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$1,567
- Inspire$1,119
- REXULTI$772
- Austedo XR$723
- JARDIANCE$604
- TARPEYO$375
- Fanapt$358
- XOLAIR$292
- VOQUEZNA$255
- Xhance$250
- Vemlidy$246
- DOVATO$243
- Auvelity$241
- MYFEMBREE$150
- TECENTRIQ$144
- Cochlear Nucleus CI632 cochlear implant with Slim Modiolar electrode$144
- Baha$144
- OSIA OSI300 IMPLANT$144
- REZDIFFRA$135
- Kcentra$135
How this compares
$12,222 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 15 | $1,707 |
| Levocetirizine Dihydrochloride | 51 | $792 |
| Naloxone Hcl | 12 | $733 |
| Fluticasone Propionate | 63 | $700 |
| Ofloxacin | 14 | $469 |
| Ipratropium Bromide | 19 | $448 |
| Azelastine Hcl | 15 | $409 |
| Famotidine | 18 | $284 |
| Lidocaine Hcl ViscousLidocaine Hcl | 13 | $70 |
Paid to pharmacies, not to this prescriber.
Other family in Staten Island
- John de OcaStaten Island$86K
- Daniel OstrowskiStaten Island$25K
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
- Sheri HillNorth Syracuse$165K
- Cathrine CurtinBronxville$155K
- Mary Sullivan-WhalenNew York$137K
- Sarah AljahmiRockville Centre$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.